Identification of the estrogen receptor beta as a possible new tamoxifen-sensitive target in diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype. Despite the proven efficacy of combined immunochemotherapy (R-CHOP) in the majority of patients, ~40% of DLBCL patients do not respond or will relapse and consequently have a very poor prognosis. The development of targeted t...

Descripción completa

Detalles Bibliográficos
Autores principales: Langendonk, Myra, de Jong, Mathilde R. W., Smit, Nienke, Seiler, Jonas, Reitsma, Bart, Ammatuna, Emanuele, Glaudemans, Andor W. J. M., van den Berg, Anke, Huls, Gerwin A., Visser, Lydia, van Meerten, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901714/
https://www.ncbi.nlm.nih.gov/pubmed/35256592
http://dx.doi.org/10.1038/s41408-022-00631-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901714/
https://www.ncbi.nlm.nih.gov/pubmed/35256592
http://dx.doi.org/10.1038/s41408-022-00631-7

Ejemplares similares